Full Press Release Details
Verify to continue
To continue, please confirm that you're a human (and not a spambot).
Checking if the site connection is secure
vimeo.com needs to review the security of your connection before
proceeding.
KURA Neutral Sentiment
NPM1 mutations in acute myeloid leukemia: actionable mutations to inform treatment decisions with clinical trials
Key Takeaway: The article discusses NPM1 mutations in acute myeloid leukemia and their implications for treatment decisions in clinical trials. It emphasizes the importance of identifying actionable mutations to guide therapy. However, the article does not provide specific details or findings.
Price reaction · baseline $10.27 (2023-08-08T16:37:00.000Z) · hit during market hours · clean, no other KURA news in the window
day 0 close · peak
+1.3%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+116%
120-day peak, hindsight
Typical move
5.7%
average across 9 past catalysts
Cash runway
~25 mo
Low dilution risk
Lead asset
Tipifarnib
Phase 2 · Leukemia, Myelomonocytic, Chronic